iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Alembic Pharma receives tentative approval from USFDA for Fesoterodine Fumarate

2 Feb 2022 , 09:39 AM

In its press release on Wednesday, Alembic Pharmaceuticals Limited announced that the company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fesoterodine Fumarate ExtendedRelease Tablets, 4 mg, and 8 mg.

The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Toviaz Extended-Release Tablets, 4 mg, and 8 mg, of Pfizer Inc. (Pfizer). Fesoterodine Fumarate ExtendedRelease Tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses.

Fesoterodine Fumarate Extended-Release Tablets, 4 mg, and 8 mg have an estimated market·size of US$ 225 million for twelve months ending September 2021 according to IQVIA.

Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company, engaged in the healthcare sector since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products around the world.

Alembic Pharma is currently trading at Rs769.15 up by Rs7 or 0.92% from its previous closing of Rs762.15 on the BSE. The scrip opened at Rs762.20 and has touched an intraday high and low of Rs772.90 and Rs761.75 respectively.

Related Tags

  • Alembic Pharma News
  • Alembic Pharma Stock
  • Alembic Pharma Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.